

# Immune modulation by Fas ligand reverse signaling: lymphocyte proliferation is attenuated by the intracellular Fas ligand domain

Katharina Lückerath,<sup>1</sup> Vladimir Kirkin,<sup>1</sup> Inga Maria Melzer,<sup>1</sup> Frederic B. Thalheimer,<sup>1</sup> Dagmar Siele,<sup>1</sup> Wiebke Milani,<sup>1</sup> Thure Adler,<sup>2</sup> Antonio Aguilar-Pimentel,<sup>3</sup> Marion Horsch,<sup>2</sup> Geert Michel,<sup>2</sup> Johannes Beckers,<sup>2,4</sup> Dirk H. Busch,<sup>5</sup> Markus Ollert,<sup>3</sup> Valerie Gailus-Durner,<sup>2</sup> Helmut Fuchs,<sup>2</sup> Martin Hrabě de Angelis,<sup>2,4</sup> Frank J. T. Staal,<sup>6</sup> Krishnaraj Rajalingam,<sup>7</sup> Anne-Odile Hueber,<sup>8</sup> Lothar J. Strobl,<sup>9</sup> Ursula Zimmer-Strobl,<sup>9</sup> and Martin Zörnig<sup>1</sup>

<sup>1</sup>Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, Frankfurt, Germany; <sup>2</sup>German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg/Munich, Germany; <sup>3</sup>Clinical Research Division of Molecular and Clinical Allergotoxicology, Department of Dermatology and Allergy Biederstein, Technische Universität München, Munich, Germany; <sup>4</sup>Chair for Experimental Genetics, Technische Universität München, Freising-Weihenstephan, Germany; <sup>5</sup>Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany; <sup>6</sup>Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands; <sup>7</sup>Institute for Biochemistry II, Goethe University Medical School, Frankfurt, Germany; <sup>8</sup>University of Nice-Sophia Antipolis, Centre National de la Recherche Scientifique, Equipe labellisée La Ligue, Institute of Developmental Biology and Cancer, Nice, France; and <sup>9</sup>Department of Gene Vectors, Helmholtz Zentrum München, Munich, Germany

**Fas ligand (FasL) not only induces apoptosis in Fas receptor-bearing target cells, it is also able to transmit signals into the FasL-expressing cell via its intracellular domain (ICD). Recently, we described a Notch-like proteolytic processing of FasL that leads to the release of the FasL ICD into the cytoplasm and subsequent translocation into the nucleus where it may influence gene transcription. To study the molecular mechanism underlying such reverse FasL signaling in detail and to analyze its physiological importance in**

**vivo, we established a knockout/knockin mouse model, in which wild-type FasL was replaced with a deletion mutant lacking the ICD. Our results demonstrate that FasL ICD signaling impairs activation-induced proliferation in B and T cells by diminishing phosphorylation of phospholipase C  $\gamma$ , protein kinase C, and extracellular signal-regulated kinase 1/2. We also demonstrate that the FasL ICD interacts with the transcription factor lymphoid-enhancer binding factor-1 and inhibits lymphoid-enhancer binding factor-**

**1-dependent transcription. In vivo, plasma cell numbers, generation of germinal center B cells, and, consequently, production of antigen-specific immunoglobulin M antibodies in response to immunization with T cell-dependent or T cell-independent antigen are negatively affected in presence of the FasL ICD, suggesting that FasL reverse signaling participates in negative fine-tuning of certain immune responses. (*Blood*. 2011; 117(2):519-529)**

## Introduction

Fas ligand (FasL, CD95L, CD178, TNFSF6) is a 40-kDa glycosylated type II transmembrane protein that belongs to the tumor necrosis factor (TNF) family. Its extracellular portion harbors a C-terminal TNF homology domain that assembles as homotrimers and mediates interactions with receptors. Interestingly, the 77-amino acid (aa)-long N-terminal mouse FasL intracellular domain (ICD) contains several conserved signaling motifs, such as a tandem casein kinase I phosphorylation site (aa 17-21), a proline-rich domain (PRD; aa 45-69) that serves as a docking site for SH3 domain-containing proteins, and a tyrosine phosphorylation site located at aa 7.<sup>1</sup>

The FasL/Fas receptor system is renowned as a potent inducer of apoptosis in the receptor-bearing cell and is especially important for numerous immune system functions, including removal of target cells by natural killer and cytotoxic T cells, (self) elimination of effector cells after the proliferative phase of an immune response (activation-induced cell death), and maintenance of immune-privileged sites.<sup>2,3</sup> Naturally occurring homozygous mutations of

the *Fas* (*lpr*) and the *FasL* (*gld*) genes, which abolish Fas-mediated apoptosis, lead to development of a severe lymphoproliferative disease.<sup>4</sup>

Because of its potent proapoptotic potential and important function, expression and activity of FasL is tightly regulated at transcriptional and posttranslational levels and is restricted to a few cell types, such as immune effector cells and cells of immune-privileged sites (eg, eyes, testis, brain). In contrast, the Fas receptor is expressed in a wide variety of tissues, including the lymphoid tissues, liver, heart, and ovary.<sup>1,5</sup>

In addition to its pro-death function, the Fas/FasL system also transduces nonapoptotic signals into the Fas-expressing cells. Among others, Fas is required for cell survival, proliferation and activation of T cells, liver regeneration, and neurogenesis.<sup>6,7</sup>

A number of studies have presented evidence for alternative signal transduction via “reverse signaling” into the FasL-bearing cells, although conflicting data have been published regarding the functional implications (for review see Voss et al<sup>1</sup>). First evidence

Submitted July 1, 2010; accepted October 5, 2010. Prepublished online as *Blood* First Edition paper, October 22, 2010; DOI 10.1182/blood-2010-07-292722.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

The online version of this article contains a data supplement.

© 2011 by The American Society of Hematology

for the existence of retrograde FasL signaling stems from 2 studies that demonstrated either costimulation of murine CD8<sup>+</sup> cytotoxic T lymphocyte (CTL) cell lines upon FasL cross-linking<sup>8</sup> or inhibition of activation-induced proliferation in murine CD4<sup>+</sup> T cells.<sup>9</sup> In both cases, FasL reverse signaling could only be observed under conditions of suboptimal T-cell receptor (TCR)–stimulation and in the presence of signaling-competent FasL. According to *in vitro* experiments, the FasL PRD domain is sufficient for costimulation of T cells, which includes FasL recruitment into rafts, enhancement of AKT, extracellular signal-regulated kinase 1/2 (ERK1/2), JNK and FasL phosphorylation, activation of nuclear factor of activated T cells (NFAT) and activator protein 1, and increased interferon- $\gamma$  production.<sup>10</sup> Remarkably, inhibition of T-cell activation by FasL reverse signaling has been associated with reduced phosphorylation of ERK1/2, linker of activated T cells, phospholipase C  $\gamma$  (PLC $\gamma$ ), and  $\zeta$ -chain-associated protein kinase 70, and with diminished TCR internalization.<sup>11</sup> Considering these conflicting results, it is clear that a physiological *in vivo* model system is required to elucidate the mechanism and role of FasL reverse signaling.

Recently, we discovered a Notch-like processing of FasL by the proteases a disintegrin and metalloprotease 10 (ADAM10) and signal peptide peptidase-like 2a (SPPL2a), which leads to the release of the FasL ICD into the cytoplasm and subsequent translocation to the nucleus where it may influence gene transcription.<sup>12</sup> These results strongly suggest that the intracellular FasL domain is responsible for reverse signal transmission into the FasL-bearing cell.

Several FasL binding partners have been identified, the majority of which interact with the FasL PRD domain via their SH3 domains (for review see Voss et al<sup>1</sup>). We reported a ternary complex consisting of FasL, the SH3 domain-containing adaptor protein PSTPIP (proline, serine, threonine phosphatase interacting protein) and the phosphatase PTP-PEST (protein tyrosine phosphatase, nonreceptor type, 12; PTPN12). According to our data, formation of this complex reduces FasL cell surface expression by promoting its intracellular storage, which correlates with a decreased FasL-dependent killing capacity.<sup>13</sup>

As the precise molecular mechanism underlying FasL reverse signaling and its physiological relevance have not been addressed at the endogenous protein level *in vivo*, we have established a knockout/knockin mouse model in which wild-type FasL was replaced with a deletion mutant lacking the intracellular portion (*FasL  $\Delta$ Intra*). In this study, we show that signaling via the FasL ICD dampens the activation-induced proliferative response of lymphocytes by impairing PLC $\gamma$ , protein kinase C (PKC) and ERK1/2 phosphorylation and by affecting target gene regulation. We found that interaction of the FasL ICD with the transcription factor lymphoid-enhancer binding factor-1 (Lef-1) regulates Lef-1–dependent transcription. *In vivo* T cell–dependent (TD) immunization with 3-hydroxy 4-nitrophenylacetyl chicken gamma globulin (NP-CGG) revealed elevated numbers of plasma cells (PCs) and a significantly increased generation of germinal center B cells (GCs) in response to the immunization in homozygous *FasL  $\Delta$ Intra* mice, leading to increased titers of NP-specific immunoglobulin M (IgM) antibodies in the serum. Similarly, T cell–independent (TI)–immunization with NP-Ficoll led to significantly higher PC numbers and NP-specific IgM antibody titers in mutant mice. Our *in vivo* findings based on endogenous FasL protein levels demonstrate that FasL reverse signaling functions as a negative modulator of certain immune responses.

## Methods

### Generation of *FasL $\Delta$ Intra* animals, genotyping of mice

Mice were housed and handled according to the federal animal welfare guidelines, and all mice studies were approved by the state ethics committee. The mouse *FasL* gene was subcloned from a 129Sv genomic BAC clone into the *pBluescript* vector (Stratagene). The *AfeI/PstI* fragment, which comprises most of exon 1, was replaced with a polymerase chain reaction (PCR)–generated fragment in which aa 2–74 from the N terminus of FasL were deleted. A *tk-neo* cassette flanked by 2 *loxP* sites was placed into the blunted *EcoRI* site in intron 1, and a diphtheria toxin A gene cassette was placed downstream of the 3' homology arm for negative selection (see Figure 1A). The linearized targeting construct was electroporated into the 129  $\times$  1/SvJ-derived mouse embryonic stem (ES) cell line TBV2. G418-resistant clones were screened for homologous recombination at the *FasL* locus by Southern blot analysis of a *BamHI* fragment covering exon 1 and 2 (see supplemental Figure 1, available on the Blood Web site; see the Supplemental Materials link at the top of the online article). Successfully targeted ES cells were injected into C57Bl/6 blastocysts and transferred into pseudopregnant CD-1 foster mothers to obtain chimeric animals. Germline transmission in mice generated by mating chimeric males with C57Bl/6 females was detected by coat color and reconfirmed by Southern analysis of tail DNA.

To remove the floxed *tk-neo* selection cassette in the germ line, mice were crossed with the early deleter transgenic mouse strain *CMV-Cre. FasL  $\Delta$ Intra* mice were backcrossed into the C57Bl/6N genetic background, and offspring were routinely genotyped by PCR with 2  $\mu$ L of the genomic DNA as template, Red Taq genomic DNA Polymerase (Sigma-Aldrich), and primers amplifying the region around the remaining *loxP* site in intron 1 of the mutated allele (forward 5'-CCATGAAATCATTATGGTTGGGG-3'; reverse 5'-GAACAAGACACAAAATTGATTTTCAT-3'). PCR cycling conditions included an annealing temperature of 57°C.


For expression of the mutant FasL protein in the Fas-deficient *lpr,lpr* background, *FasL  $\Delta$ Intra* mice were mated with *lpr* animals (*FasB6.MRL-Faslpr/lpr*) to obtain homozygous *lpr,lpr* offspring that express either wild-type or truncated FasL (*lpr,lpr/FasL* wild-type, *FasL* wild-type and *lpr,lpr/FasL  $\Delta$ Intra,FasL  $\Delta$ Intra*). To genotype for the *lpr* mutation, a 3-primer strategy was used using the following primer sequences: *lpr*-common 5'-GTAAATAATTGTGCTTCGTCAG-3', *lpr*-wild-type 5'-CAATCTAGGCATTAACAGTG-3', *lpr*-mutant 5'-TAGAAAGGTG-CACGGGTGTG-3'. Primers were used at 20  $\mu$ M each and annealed at 59°C according to the protocol provided by The Jackson Laboratory.

Additional detailed experimental procedures are described in the supplemental Data section.

## Results

### Generation of knockout/knockin mice that express mutant FasL lacking the intracellular domain

To study reverse signaling via the FasL ICD *in vivo*, the mouse line *FasL  $\Delta$ Intra* was established that expresses a truncated FasL molecule without the N-terminal ICD instead of the wild-type protein. *Exon 1* was shortened by the DNA sequences coding for FasL aa 2–74 in the targeting construct, and a *tk-neo* cassette flanked by *loxP* sites was placed into *intron 1* to allow selection of ES cells that had undergone monoallelic homologous recombination (Figure 1A). Correctly targeted ES clones (supplemental Figures 1–2), were injected into C57Bl/6 blastocytes and transferred into CD1 foster mice. Breeding of the resulting heterozygous *FasL* knockout/knockin mice with *CMV-Cre* transgenic animals resulted in constitutive elimination of the *tk-neo* cassette in the germ line (supplemental Figure 2). Correct insertion of the desired mutation at the *FasL* locus was confirmed by sequence analysis of



**Figure 1. Establishment and validation of knockout/knockin mice that lack the intracellular FasL domain.** (A) Targeting strategy for the establishment of *FasL*  $\Delta$ Intra mice. DNA sequences coding for the first 73 amino acids were deleted in exon 1, and a *tk-neo* selection cassette flanked by *loxP* sites was inserted into intron 1. Subsequent excision of this cassette by Cre recombinase left a single *loxP* site in the genome. (B) T and B lymphocytes from homozygous *FasL*  $\Delta$ Intra mice express the truncated FasL molecule lacking the intracellular domain. Left panel, surface expression of full-length and mutant FasL molecules at the surface of activated lymphocytes isolated from wild-type and homozygous *FasL*  $\Delta$ Intra mice. Freshly isolated lymphocyte populations from spleen were stimulated with plate-coated 5  $\mu$ g/mL anti-CD3 antibody (T cells), or with 10  $\mu$ g/mL LPS (B cells) for 24 hours. One representative experiment of 4 is shown. Wild-type cells are represented by the solid lines, *FasL*  $\Delta$ Intra cells by the dotted lines, and the isotype control by the wide dashed lines. Right panel, RT-PCR analysis reveals *FasL*  $\Delta$ Intra mRNA expression in T and B cells. Total RNA was isolated from purified splenic wild-type and *FasL*  $\Delta$ Intra T and B cells, which had been stimulated for 24 hours with 1  $\mu$ g/mL anti-CD3 (T cells) or for 4 hours with 1  $\mu$ g/mL anti-IgM (B cells). The primer pair used for RT-PCR amplification of the FasL ICD allowed to distinguish cDNA from genomic DNA template (intron-spanning). (C) T cells isolated from homozygous *FasL*  $\Delta$ Intra mice retain the ability to kill in a FasL-dependent manner. The killing capacity of restimulated T cell blasts (10  $\mu$ g/mL anti-CD3 antibody, 24 hours) from wild-type, *FasL*  $\Delta$ Intra and both homozygous and heterozygous *gld* mice was determined by coculture experiments. Fas-sensitive, CFSE-labeled A20 target cells were used at an effector:target ratio of 2.5:1 for 6 hours in the presence of 10  $\mu$ g/mL anti-CD3 antibody. Killing capacity is expressed as the percentage of apoptotic subG1 A20 target cells minus the percentage of dead cells observed in the presence of 100  $\mu$ g/mL Fas:Fc. Columns represent the mean and bars the SE of 4 individual experiments.

genomic DNA (supplemental Figure 3). For the following studies, *FasL*  $\Delta$ Intra mice were bred into a pure C57Bl/6N genetic background.

### The truncated FasL molecule is expressed on the surface of activated *FasL* $\Delta$ Intra lymphocytes and is capable of inducing apoptosis


First, we analyzed whether the truncated FasL protein lacking the intracellular domain was expressed by activated lymphocytes of the *FasL*  $\Delta$ Intra mouse model, and whether it retained its killing capability. Reverse transcription PCR (RT-PCR) analysis using intron-spanning primer pairs and RNA isolated from both wild-type and mutant T and B cells revealed that *FasL*  $\Delta$ Intra mRNA is expressed in both cell types, and flow cytometric analysis of activated T and B cells confirmed comparable FasL cell surface expression in wild-type and *FasL*  $\Delta$ Intra lymphocytes (Figure 1B and supplemental Figure 4).

Coculture with Fas-expressing A20 target cells confirmed that cells derived from homozygous *FasL*  $\Delta$ Intra mice retained the ability to kill in a FasL-dependent manner (Figure 1C), although less efficient than wild-type cells. This decrease in cytotoxicity is consistent with our earlier finding that FasL only displays maximum killing potential when it is localized in rafts, which requires the presence of the ICD.<sup>14</sup> However, *FasL*  $\Delta$ Intra T cells are clearly more potent at inducing Fas-mediated apoptosis than T cells isolated from heterozygous or homozygous *gld* mice. Only the latter develop the lymphoproliferative disease and accumulate an aberrant CD3<sup>+</sup>B220<sup>+</sup>CD4<sup>-</sup>CD8<sup>-</sup> T-cell population and autoanti-

bodies, while the remaining FasL killing capacity in *gld/wt* heterozygous mice is already sufficient to completely prevent *gld*-associated pathology.<sup>4</sup> Systemic first-line phenotyping at the German Mouse Clinic (GMC;<sup>15,16</sup>) revealed that unchallenged homozygous *FasL*  $\Delta$ Intra mice do not display any phenotypic anomalies, exhibit normal T- and B-cell populations, no abnormality in Ig levels, and do not develop a *gld*-like lymphoproliferative disease (data not shown). The expression levels of Fas on the cell surface of lymphocytes are also normal (eg, see supplemental Figure 9A for T cells). Therefore, *FasL*  $\Delta$ Intra mice represent a suitable model to study the consequences of FasL reverse signaling deficiency in vivo.

### Absence of the intracellular FasL domain leads to increased activation-induced lymphocyte proliferation

Because the intracellular FasL domain has been implicated in the regulation of T-cell proliferation in several in vitro studies,<sup>8-11</sup> we investigated activation-induced lymphocyte proliferation in reverse signaling-deficient *FasL*  $\Delta$ Intra mice. For this purpose, naive CD4<sup>+</sup> or CD8<sup>+</sup> T cells and B cells were isolated from the spleen, stained with carboxyfluorescein succinimidyl ester (CFSE) and activated for 72 hours with anti-CD3 or F(ab')<sub>2</sub> anti-IgM antibody. Proliferation of living cells was then quantified by flow cytometry. Surprisingly, T cells lacking the FasL ICD proliferated more vigorously than wild-type cells. In B cells, this increase in activation-induced proliferation was even stronger, as seen for both, anti-IgM (Figure 2A) and anti-CD40 (supplemental Figure 5) antibody stimulation. Interestingly, differences in the proliferative



**Figure 2. Increased ex vivo lymphocyte proliferation in the absence of the intracellular FasL domain.** (A) CFSE-labeled lymphocytes were either treated for 72 hours with 5  $\mu$ g/mL coated anti-CD3 antibody (T cells), for 72 hours with 2.5  $\mu$ g/mL soluble F(ab')<sub>2</sub> anti-IgM antibody (B cells) or were left untreated (filled gray peaks, negative control). B cells (top panel), CD4<sup>+</sup> CD25<sup>-</sup> helper T cells without regulatory T cells (middle panel) and CD8<sup>+</sup> cytotoxic T cells (bottom panel) were isolated from splenocytes. Activation-induced proliferation of living cells (propidium iodide negative) was measured by FACS analysis, as represented by the decrease in CFSE fluorescence intensity. The solid line represents wild-type cells while the dotted line represents cells from homozygous *FasL ΔIntra* mice. One representative experiment of 5 (T cells) or 1 of 4 (B cells) is shown. (B) The observed differences in proliferation are not due to differences in activation-induced cell death. Lymphocytes used for the CFSE proliferation assays were simultaneously seeded under identical conditions for annexinV/PI staining. The number of dead cells was quantified 48 and 72 hours after stimulation with anti-IgM (B cells) or plate-bound anti-CD3 (T cells) antibodies by FACS analysis. Dark gray columns represent wild-type and light gray columns *FasL ΔIntra* cells. The columns display the mean and bars the SE of 5 individual experiments.

capacity of CD4<sup>+</sup> T cells could only be detected ex vivo after depletion of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells (T<sub>regs</sub>). In the presence of T<sub>regs</sub>, the proliferative response of *FasL ΔIntra* T cells was indistinguishable from wild-type cells (data not shown). Increased proliferation of T and B cells expressing mutant FasL was not due to diminished activation-induced cell death as measured by annexin V/propidium iodide staining (Figure 2B). These data imply that reverse signaling via the FasL ICD dampens lymphocyte proliferation.

#### FasL reverse signaling dampens the immune response following TD and TI immunization

Immune responses against antigens are mediated by the expansion of antigen-specific lymphocyte populations. Because FasL reverse signaling influenced activation-induced proliferation in lymphocytes ex vivo, we assessed whether FasL ICD-dependent signaling would also affect B-cell proliferation following antigen exposure in vivo. For this purpose, wild-type and homozygous *FasL ΔIntra* mice were immunized with NP-CGG,<sup>17</sup> and the following formation of germinal centers was analyzed 14 days later by fluorescence-activated cell sorting (FACS). We observed elevated numbers of Syndecan<sup>+</sup>B220<sup>low</sup> PCs and a significant higher increase in Fas<sup>+</sup>PNA<sup>+</sup> GCs in *FasL ΔIntra* mice (Figure 3A-B), a finding that correlated with significantly increased titers of NP-specific IgM and a trend toward elevated NP-specific IgG1 serum antibodies (Figure 3C). In the same animals, no differences were detected in the amounts of B220<sup>+</sup>IgM<sup>high</sup>IgD<sup>low</sup> marginal zone B cells and


B220<sup>+</sup>IgM<sup>+</sup>IgD<sup>+</sup> follicular B cells (data not shown). Likewise, no alterations were found in the T:B cell ratio and in the number of activated B cells before and 14 days after immunization (data not shown).

To exclude that the higher PC numbers and IgM antibody titers are due to an impaired T cell-dependent negative selection of GC B cells, we immunized wild-type and *FasL ΔIntra* mutant mice with the TI antigen NP-Ficoll (Figure 3D-E). Similar to the TD immunization, we observed significantly elevated numbers of PCs (Figure 3D) and titers of NP-specific IgM antibodies (Figure 3E top panel) and a trend toward higher levels of NP-specific IgG3 antibodies (Figure 3E bottom panel) 7 days after immunization. Besides NP-specific IgM levels, only titers of antigen-specific IgG1 or IgG3 antibodies were determined, as the majority of B cells switch to these Ig isotypes following TD (IgG1) or TI (IgG3) immunization.<sup>18,19</sup>

These observations suggest that signaling via the FasL ICD participates in the regulation of T cell-dependent and independent immune responses by dampening lymphocyte activation and expansion.

#### The intracellular FasL domain regulates ERK1/2 activation and proliferation via PLC $\gamma$ 2 and PKC in B cells

B-cell receptor (BCR) and TCR signaling involves activation of the ERK/mitogen-activated protein kinase (MAPK) cascade, which can be assessed by monitoring ERK1/2 phosphorylation.<sup>20</sup> To



**Figure 3. Signaling via the FasL ICD modulates the immune response following immunization with NP-CGG.** Wild-type and *FasL*  $\Delta$ *Intra* mice were immunized with 100  $\mu$ g of the TD antigen NP-CGG (left panel) or with 50  $\mu$ g of the TI antigen NP-Ficoll (right panel; both intraperitoneal injections) and killed 14 days (NP-CGG) or 7 days (NP-Ficoll) later. The amount of Syndecan<sup>+</sup>B220<sup>low</sup> plasma B cells (A,D) and CD95<sup>+</sup>PNA<sup>+</sup> GCs (B) was determined by FACS analysis of splenocytes. The data represent results from 2 immunization experiments, each time with 4 (NP-CGG) or 5 (NP-Ficoll) mice per group. The columns represent mean values of the individual animals, and the bars indicate the standard error. (C,E) Titers of antigen-specific, NP17-binding IgM, IgG1 (C), or IgG3 (E) antibodies in the serum of immunized animals were determined by ELISA. Each symbol represents 1 mouse, and the vertical bar indicates the mean value per group. Immunglobulin titers in the serum of wild-type mice are represented by filled hash keys and titers in *FasL*  $\Delta$ *Intra* mice by open rectangles.

identify a molecular correlate for the differential activation-induced proliferation of *FasL*  $\Delta$ *Intra* and wild-type lymphocytes, naive splenic B cells were stimulated with anti-IgM for various time points, and ERK1/2 activation was quantified by enzyme-linked immunosorbent assay (ELISA). Five minutes after BCR cross-linking, the relative amount of phosphorylated ERK1/2 was significantly higher in *FasL*  $\Delta$ *Intra* cells compared with wild-type B cells, and phospho-ERK1/2 levels remained elevated throughout the entire time course of the experiment (Figure 4A). This finding was confirmed by an antiphospho-ERK1/2 Western blot analysis of cell lysates prepared from activated *FasL*  $\Delta$ *Intra* and wild-type B cells (Figure 4B).


We then tried to further characterize the signaling pathway leading to differential ERK1/2 activation in *FasL*  $\Delta$ *Intra* and wild-type B cells. Cross-linking of the BCR leads to activation of the protein tyrosine kinases Syk and Btk, which are both required for PLC $\gamma$ 2 activation.<sup>21</sup> This ultimately results in PKC phosphorylation and triggering of the MAPK pathway upon phosphorylation of Raf and/or MEK. We analyzed the amount of phosphorylated PLC $\gamma$ 2 and PKC $\alpha$  by intracellular FACS staining over a time period of 30 minutes following activation of naive B cells with F(ab')<sub>2</sub> anti-IgM antibody. Interestingly, we observed a significant

higher induction of PLC $\gamma$ 2 and PKC $\alpha$  activity in B cells derived from homozygous *FasL*  $\Delta$ *Intra* mice compared with wild-type cells (Figure 4C-D). We confirmed the differences in the amount of activated PKC $\alpha$  by Western Blot analysis (supplemental Figure 6). The importance of PKC activation for B-cell stimulation is underlined by the strong inhibition of ERK1/2 phosphorylation (Figure 4E) and proliferation (Figure 4F) of naive wild-type and homozygous *FasL*  $\Delta$ *Intra* B cells when the cells were simultaneously treated with a pan-PKC inhibitor (GF109203x hydrochloride).

Collectively, our data confirm that in activated *FasL*  $\Delta$ *Intra* B cells, phosphorylation of PLC $\gamma$ 2, PKC, and ERK1/2 is increased compared with wild-type cells, leading to augmented proliferation. Our data suggest that the FasL ICD diminishes activation-induced lymphocyte proliferation by interfering with early molecular events following cross-linking of the BCR.

#### The intracellular FasL domain interacts with Lef-1 and inhibits Lef-1-dependent transcription

In a yeast-2-hybrid screen using the FasL ICD as bait, we identified the transcription factor Lef-1 as a putative interaction partner of the




**Figure 4. The FasL ICD dampens ERK1/2 activity during B cell activation by inhibiting PKC $\alpha$  phosphorylation.** (A) Increased ERK1/2 phosphorylation in activated homozygous *FasL*  $\Delta$ *Intra* B cells. Naive splenic B cells were stimulated with 1  $\mu$ g/mL soluble anti-IgM antibody for the indicated time points and analyzed for ERK1/2 phosphorylation by ELISA. The diagram displays the relative induction of ERK1/2 activation over time during anti-IgM treatment, measured as the increase in relative fluorescence intensity of phosphorylated ERK1/2 compared with total ERK1/2 protein. Wild-type cells are represented by the dark gray columns and homozygous *FasL*  $\Delta$ *Intra* cells by light gray columns. Mean values of 4 independent experiments are shown, and the error bars indicate the SE. (B) Western Blot analysis of total cell lysates prepared from wild-type and homozygous *FasL*  $\Delta$ *Intra* splenic B cells that were stimulated for 0, 5, 10, and 30 minutes with 1  $\mu$ g/mL anti-IgM antibody. Phosphorylated ERK1/2 was detected with a rabbit anti-mouse pERK1/2 antibody;  $\beta$ -actin served as a loading control. (C,D) The activating phosphorylation of PLC- $\gamma$ 2 and PKC $\alpha$  is repressed by the FasL ICD. Activation of PLC- $\gamma$ 2 (C) and PKC $\alpha$  (D) after stimulation of naive wild-type and homozygous *FasL*  $\Delta$ *Intra* splenic B cells with 25  $\mu$ g/mL F(ab) $_2$  anti-IgM antibody for the indicated times was evaluated by intracellular staining of the phosphorylated proteins, followed by FACS analysis. The relative geometric mean fluorescent intensity (MFI) of activated cells was calculated against the MFI of untreated cells. Mean data of 11 (PLC- $\gamma$ 2) and 12 (PKC $\alpha$ ) independent experiments are shown together with standard errors. (E) ERK1/2 activation in activated mouse B cells is PKC $\alpha$ -dependent. ERK phosphorylation, in response to B cell stimulation with 1  $\mu$ g/mL anti-IgM antibody, was determined by ELISA, either in the presence or absence of the PKC inhibitor GF109203x hydrochloride (1  $\mu$ M). Wild-type cells are illustrated by solid and homozygous *FasL*  $\Delta$ *Intra* cells by striped columns. The gray color represents cells without and the black color the corresponding inhibitor-treated cells. (F) PKC $\alpha$  regulates FasL reverse signaling-influenced B cell proliferation. Proliferation of wild-type and homozygous *FasL*  $\Delta$ *Intra* naive splenic B cells in response to stimulation with 100 ng/mL PMA and 0.2  $\mu$ g/mL ionomycin in the presence (1  $\mu$ M) or absence of the PKC inhibitor GF109203x hydrochloride (Sigma-Aldrich) was measured after 72 hours by a FACS-based CFSE dilution assay. Nonstimulated cells are represented by the light gray-filled histogram. The solid line shows activated B cells without PKC inhibitor, the dotted line indicates the activated inhibitor-treated cells. One representative experiment of 4 is shown.

cytoplasmic FasL domain (data not shown). To confirm the interaction, we performed in vitro glutathione S-transferase (GST) pull-down assays. A full-length Lef-1 GST fusion protein was able to co-precipitate in vitro translated full-length FasL and the sole FasL ICD (Figure 5A left and middle panels), and GST-FasL ICD could coprecipitate in vitro translated Lef-1 (Figure 5A right panel). We verified the FasL-Lef-1 interaction in coimmunoprecipitation experiments with lysates prepared from transfected HEK293T cells (Figure 5B).

Lef-1 is a member of the LEF/TCF transcription factor family that mediates the nuclear response to Wnt signaling, which is increasingly being recognized as important for hematopoiesis, lymphopoiesis, and immune function.<sup>22</sup> To study the functional consequences of the FasL-Lef-1 interaction, we quantified Lef-1-dependent transcription in the presence of various FasL ICD concentrations using the TOP/FOP Lef-1 reporter system (Figure 5C). After cotransfecting *FasL* ICD with either TOP or FOP

*luciferase* reporter plasmids into HEK293T cells, Lef-1 signaling was stimulated with LiCl, which mimics canonical Wnt signaling, and Luciferase reporter activity was quantified. Interestingly, the FasL ICD repressed Lef-1-dependent transcription of the *luciferase* gene in a concentration-dependent manner. Similar results were obtained with the specific GSK3 $\beta$  inhibitor SB-216763 instead of LiCl to induce Lef-1/ $\beta$ -catenin-mediated transcription (supplemental Figure 7). Collectively, our data demonstrate that the FasL ICD interacts with Lef-1 to regulate Lef-1-dependent transcription.

While elevated expression of Lef-1 and an important function for Lef-1-dependent Wnt signaling has been shown in B-cell progenitors,<sup>23,24</sup> less information is known about expression and function of Lef-1 in mature B lymphocytes. Therefore, we analyzed Lef-1 expression in mature splenic B cells. RT-PCR analysis with RNA prepared from activated B cells revealed the presence of *Lef-1* mRNA (Figure 5D top panel). In addition, we could detect




**Figure 5. The intracellular FasL domain binds to Lef-1 and influences its transcriptional activity.** (A) In vitro GST pull-down experiments reveal FasL-Lef-1 interaction. Top panel, pull-down of in vitro translated  $^{35}\text{S}$  FasL (left), FasL ICD (middle), and Lef-1 (right) proteins with the indicated bacterially expressed GST fusion proteins. The black arrows mark in vitro translated proteins that specifically interact with the GST fusion molecules. GST-PSTPIP serves as a positive control for FasL binding<sup>13</sup> and GST protein only as a general negative control. Bottom panel, Coomassie-stained protein gels showing purified GST fusion proteins. Arrows indicate the GST fusion proteins used for the above GST pull-down experiment. (B) Coimmunoprecipitation of overexpressed Flag-FasL and Lef-1 proteins. HEK 293T cells were transfected with *Lef-1* and *FasL* or empty vector (*pcDNA3.1*). Forty-eight hours later, cell lysates were prepared and immunoprecipitations performed with anti-Flag M2 (binding to Flag-tagged FasL) or anti-FasL (NOK1) antibodies. Western Blot analysis with the anti-Lef-1 antibody revealed for both coimmunoprecipitation reactions binding of Flag-FasL to Lef-1 (top panel). Control incubation of the membrane with anti-Flag antibody confirmed the presence and successful immunoprecipitation of Flag-FasL (middle panel right side); the input Western Blot analysis with anti-Lef-1 antibody (bottom panel) demonstrated presence of transfected Lef-1. (C) The FasL ICD represses Lef-1/ $\beta$ -catenin activity in a Luciferase reporter assay. HEK293T cells were cotransfected with the indicated increasing amounts of the *FasL ICD* together with optimal (TOP) or mutated (FOP, negative control) *Firefly luciferase* reporter constructs for Lef-1 activity. Sixteen hours after cultivation of the cells in the presence of 30mM LiCl to inhibit GSK3 $\beta$ , Lef-1-dependent *Luciferase* activity was quantified in the cell lysates. *Firefly luciferase* activity was normalized to *Renilla luciferase* activity, and the value obtained for TOP plasmid without *FasL ICD* was set to 1. All samples were measured in triplicates. Control transfections with TOP plasmid alone without LiCl did not induce *luciferase* activity (data not shown). The columns represent the mean of 3 individual experiments, and error bars indicate the standard deviation. Statistical significance was assessed using Student *t* test (\* $P < .05$ ; \*\* $P < .01$ ; \*\*\* $P < .001$ ). (D) RNA and protein expression analysis of Lef-1 in mature B cells. Top panel, RT-PCR experiment with intron-spanning *Lef-1*-specific PCR primers and total RNA isolated from wild-type and *FasL ΔIntra* splenic B cells that were stimulated with 1  $\mu\text{g}/\text{mL}$  anti-IgM antibody for 4 hours. RNA prepared from *Lef-1*-transfected HEK 293T cells served as a positive control, while water without RNA template was used as a negative control. Bottom panel, histogram of intracellular FACS staining confirms expression of Lef-1 in B cells. Naive splenic B cells were fixed, permeabilized, and incubated subsequently with anti-Lef-1 and secondary antibody. The solid curve represents wild-type cells, the dotted curve represents the *FasL ΔIntra* B cells, and the filled gray curve depicts the isotype control. One representative experiment of 6 is displayed.

significant Lef-1 protein expression in both wild-type and *FasL ΔIntra* B cells by intracellular FACS staining (Figure 5D bottom panel). The expression of both proteins, FasL and Lef-1, in B and T cells enables regulation of Lef-1-dependent Wnt signaling by the FasL ICD in lymphocytes.

#### FasL reverse signaling regulates proliferation-associated and Wnt pathway-related target genes

Based on the observed interaction of the FasL ICD with Lef-1 and its influence on the transcriptional activity of a transfected Lef-1 reporter construct, we analyzed global gene expression patterns in activated B cells from wild-type and *FasL ΔIntra* mice. We observed profound differences in the mRNA levels of several candidate genes, including Wnt pathway-associated genes (data not shown). The differential expression of a number of genes in

wild-type and *FasL ΔIntra* B cells was then verified by quantitative RT-PCR. Several genes implicated in lymphocyte proliferation and activation, such as *NFATc1*,<sup>25</sup> *NF- $\kappa$ B1/p50*,<sup>26</sup> and interferon regulatory factor 4 (*IRF4*)<sup>27</sup> were significantly up-regulated in the absence of the FasL ICD (Figure 6), a finding that correlates with the increased proliferative capacity of mutant *FasL ΔIntra* lymphocytes. Furthermore, increased expression of Wnt-related genes, such as *Cyclin D1*,<sup>28</sup> *Survivin*,<sup>29</sup> *ectodysplasin A (EDA)*,<sup>30</sup> and *fibroblast growth factor 4 (FGF 4)*<sup>31</sup> was confirmed in *FasL ΔIntra* B cells. Interleukin-4 (IL-4) is negatively controlled by direct binding of Lef-1 to the *IL-4* promoter.<sup>32</sup> Consequently, we found IL-4 to be down-regulated 2-fold in *FasL ΔIntra* B cells lacking the Lef-1-inhibiting FasL ICD. These data support the model of Notch-like reverse signaling via FasL influencing gene transcription and the regulation of Wnt signaling by interaction of the FasL ICD with Lef-1 in lymphocytes.



**Figure 6. The FasL ICD regulates expression of proliferation-associated and Wnt signaling target genes.** Differential expression of selected genes, which represent direct targets of the Wnt signaling pathway and/or that are involved in lymphocyte activation and proliferation, is shown in wild-type and *FasL ΔIntra* B cells. Gene expression in both cell populations was quantified by real-time PCR with cDNA derived from stimulated splenic B cells (1 μg/mL anti-IgM antibody for 4 hours). Each sample was assessed in triplicate and normalized to the housekeeping gene *Hprt*. The relative change of gene expression in *FasL ΔIntra* cells was calculated with the comparative threshold cycle method ( $2^{-\Delta\Delta Ct}$ ). The columns for each gene represent the mean of 4 independent experiments, and the black bars indicate SEs.

## Discussion

TNF receptor family members are expressed by a wide variety of cells, whereas the majority of the 19 identified TNF ligands are found exclusively on cells belonging to the immune system. Most of the molecules function as membrane-bound proteins, and at least 10 TNF family members receive and deliver (co-)stimulatory signals through their respective receptors.<sup>33</sup>


FasL has been shown to mediate reverse signal transduction following receptor binding, however, there is conflicting *in vitro* data concerning the functional outcome.<sup>8-11</sup> Here we aimed to elucidate the physiological consequences of FasL reverse signaling at the endogenous protein level *in vivo*. For this purpose, a knockout/knockin mouse model deficient for FasL reverse signaling was established, in which wild-type FasL was replaced by a FasL deletion mutant lacking the complete intracellular domain (*FasL ΔIntra*). We demonstrated that activated lymphocytes from homozygous *FasL ΔIntra* mice express a functional truncated FasL membrane-bound protein with the capacity to induce apoptosis in Fas receptor-positive target cells. Furthermore, *ex vivo* experiments revealed that activation-induced proliferation is significantly increased in B cells, CD8<sup>+</sup> CTLs, and CD4<sup>+</sup> T cells derived from homozygous *FasL ΔIntra* mice. To our knowledge, this is the first time that FasL reverse signaling has been demonstrated in B cells. The activated FasL-mutant lymphocytes display increased phosphorylation of ERK1/2, PLCγ2, and PKCα, demonstrating that reverse signaling via the FasL ICD impedes early events following antigen stimulation of BCRs and TCRs. Interestingly, the increased proliferation of *FasL ΔIntra* T cells is reduced to wild-type levels in the presence of inhibitory CD4<sup>+</sup> CD25<sup>+</sup> regulatory T cells,<sup>34</sup> which indicates that additional control mechanisms act *in vivo*. As we did not find obvious differences in the *in vivo* proliferation of Vβ8<sup>+</sup> T cells following injection of wild-type and *FasL ΔIntra* mice with the superantigen SEB, our data substantiates the notion that regulatory T cells display an inhibitory influence on the increased activation-induced proliferation of *FasL ΔIntra* T cells (Oehme et al<sup>35</sup> and data not shown). An alternative explanation for the SEB result builds on the fact that according to several *in vitro* studies, the influence of FasL reverse signaling on T-cell proliferation is only observable under conditions of suboptimal stimulation.<sup>8-11</sup> If TCR signaling is induced, for example, by high amounts of anti-CD3 antibody, the proliferative behavior does not change upon co-triggering of FasL. SEB exerts a very strong T-cell stimulus and may override inhibitory FasL reverse signaling.

The hyperactivation of homozygous *FasL ΔIntra* lymphocytes in the absence of the FasL ICD that we observed *ex vivo* is expected to affect immune regulation *in vivo*. Indeed, the immune response following immunization with the TD antigen NP-CGG differs between *FasL ΔIntra* and wild-type mice. The number of PCs and the increase in GCs is significantly higher in the absence of the FasL ICD and leads to elevated NP-specific IgM antibody titers, thereby representing an *in vivo* finding that confirms the modulation of immune responses by FasL reverse signaling. Similarly, immunization with the TI antigen NP-Ficoll resulted in significant higher numbers of PCs and titers of NP-specific IgM antibodies, thereby ruling out that the phenotype observed after TD immunization reflects an impaired negative selection of mutant GC B cells. This notion is also supported by a comparable sensitivity of wild-type and mutant-activated B cells toward FasL/Fas-dependent cell death induced in coculture experiments with T cell blasts, and by a similar costimulatory potential (ie, CD40L expression) of activated wild-type and *FasL ΔIntra* T cells (supplemental Figure 8). According to these results, the observed differences between the immune responses of immunized wild-type and *FasL ΔIntra* mice most likely can be explained by a lack of inhibitory FasL reverse signaling in the mutant mice. However, we cannot completely exclude that at least part of the *in vivo* phenotype following TD and TI immunization is due to a reduced killing efficiency of the truncated FasL.

In addition to its critical pro-death function, the Fas receptor transmits important nonapoptotic signals, which can lead to survival and proliferation of the receptor-bearing cells,<sup>6,7</sup> and therefore, the consequences of FasL activation experiments could also be assigned to disturbance of nonapoptotic Fas receptor signaling. However, the increased activation-induced proliferation we observed in homozygous *FasL ΔIntra* lymphocytes is due to diminished FasL reverse signaling and not to increased proliferative Fas receptor signaling. This conclusion is supported by *ex vivo* proliferation assays with Fas-deficient B cells isolated from wild-type and homozygous *FasL ΔIntra* mice, both in the *lpr/lpr* genetic background. Although nonapoptotic signaling via Fas is excluded in these cells, we again noticed increased proliferation in the FasL mutant cells lacking the FasL ICD (supplemental Figure 9B). In addition, nonapoptotic Fas signaling delivers a proliferative (and not an inhibitory) stimulus,<sup>6</sup> therefore, the increased activation-induced proliferation of *FasL ΔIntra* lymphocytes that we observed would have to be explained by increased proliferative Fas signaling. However, we did not obtain evidence of enlarged Fas receptor triggering in the mutant cells: the number of



**Figure 7. Model of FasL reverse signaling and the underlying molecular mechanism.** At least 2 signaling pathways might be involved in transmitting the antiproliferative stimulus into the FasL-bearing cell. Recruitment of the tyrosine phosphatase PTP-PEST by the FasL-binding adaptor protein PSTPIP may lead to inhibition of ERK1/2 activity. In parallel, triggering of FasL followed by proteolytic cleavage of the molecule by ADAM10 and SPPL2a results in liberation of the FasL ICD into the cytoplasm, from where it translocates to the nucleus and influences gene transcription by binding to and inhibiting the transcription factor Lef-1.



Fas receptor expressing activated T cells and Fas expression levels were not augmented (supplemental Figure 9A), and the killing of target cells by *FasL ΔIntra* T cells was slightly decreased. These observations thereby argue against the notion of enhanced Fas triggering.

In our studies, we aimed to elucidate the molecular signaling events downstream of FasL triggering. The presence of the cytoplasmic FasL domain in wild-type cells causes diminished activation-induced proliferation of splenic B cells by decreasing the activating phosphorylation of PLC $\gamma$ 2, PKC, and ERK1/2, which subsequently influences target gene expression. Using various protein binding assays, we showed that an interaction occurs between the FasL ICD and the transcription factor Lef-1, which causes inhibition of Lef-1 transcriptional activity. FasL expression in mature B cells has been confirmed in different studies<sup>36-38</sup> (for review see Lundy<sup>39</sup>). Although Lef-1 expression is down-regulated during B cell development,<sup>24</sup> we could detect *Lef-1* mRNA by RT-PCR and Lef-1 protein by intracellular FACS staining in mature murine B cells. Interestingly, we measured an up-regulation of several proliferation-relevant genes in *FasL ΔIntra* B cells (eg, *IRF4*, which plays an important role in the germinal center reaction).<sup>27</sup> Because IRF4 is an important regulator of PC differentiation, increased IRF4 levels in B cells of *FasL ΔIntra* mice might contribute to the higher percentages of PCs in the spleen following immunization with NP-CGG.

Some of the genes up-regulated in activated *FasL ΔIntra* B cells represent well-known Lef-1 target genes (eg, *NFAT*,<sup>25</sup> *NF- $\kappa$ B*,<sup>26</sup> *CycD1*,<sup>28</sup> *Survivin*,<sup>29</sup> *EDA*,<sup>30</sup> and *FGF4*<sup>31</sup>). This transcriptional up-regulation correlates with and accounts for the increased proliferation of these cells. The exact molecular mechanism by which the FasL ICD inhibits Lef-1 transcriptional activity remains unclear. The binding site for FasL within the Lef-1 molecule does not overlap with the N-terminal  $\beta$ -catenin binding site,<sup>40</sup> implying that direct competition between the FasL ICD and  $\beta$ -catenin for Lef-1 binding seems implausible. Unlike most of the known FasL binding partners, Lef-1 does not contain an SH3 domain and therefore does not bind to the PRD of FasL, but rather to its extreme N terminus.

In addition, FasL may influence ERK1/2 activity and target gene expression via another pathway, independently of Lef-1. We have previously reported the existence of a ternary intracellular

protein complex consisting of FasL, the adaptor protein PST-PIP and the protein tyrosine phosphatase PTP-PEST.<sup>13</sup> Our studies demonstrated enhanced binding of PSTPIP to the FasL PRD after FasL stimulation with an agonistic antibody. PTP-PEST has been described as a negative regulator of T-cell activation.<sup>41-43</sup> PTP-PEST functions by dephosphorylating TCR-proximal signaling molecules such as Lck, Shc, Pyk2, Fak, Cas, and PLC, resulting in the inactivation of some signal transduction pathways, including Ras signaling.

Collectively, our data suggest a model in which reverse signaling via FasL attenuates transcription of genes important for proliferation by influencing at least 2 pathways (Figure 7): in one pathway, interaction of full-length FasL with PSTPIP recruits the negative ERK1/2/MAPK regulator PTP-PEST. Meanwhile, FasL also impedes proliferation following proteolysis by ADAM10 and SPPL2a, which results in liberation of the intracellular FasL domain and its binding to Lef-1 for negative regulation of Lef-1-dependent pro-proliferative Wnt signaling. Both pathways lead to diminished lymphocyte proliferation following antigen receptor stimulation.

Our *in vivo* results are consistent with other studies suggesting an inhibitory role for FasL reverse signaling in T-cell proliferation,<sup>9,11</sup> and they are in contrast to reports claiming a costimulatory function.<sup>8,10</sup> Interestingly, we also found the ERK1/2-MAPK pathway to be affected by removal of the FasL ICD, but with the opposite tendency; while Sun et al<sup>10</sup> observe increased ERK1/2 activation upon FasL costimulation, we noticed diminished ERK1/2 phosphorylation as a result of FasL reverse signaling. In the experiments showing costimulation by FasL triggering, T-cell lines were used, some of which were engineered to overexpress a rather artificial mouse FasL ICD fusion construct.<sup>10</sup> Cross-linking was induced by anti-FasL or Fas:Fc,<sup>8,10</sup> which may generate an unphysiologically strong (or weak) signal, leading to costimulation rather than inhibition; however, Paulsen et al observed decreased T-cell proliferation upon FasL engagement with the same reagents.<sup>11</sup> In our knockout/knockin system with endogenous protein expression, FasL reverse signaling is initiated by its natural inducers, which results in decreased activation-induced proliferation of primary T and B cells *ex vivo* and decreased numbers of GC and PC numbers upon immunization. Nevertheless, we performed *ex vivo* activation studies with wild-type and *FasL ΔIntra* T and

B cells (stimulated with anti-CD3 or F(ab')<sub>2</sub> anti-IgM antibodies, respectively) in the presence of coated Fas:Fc for 48 hours. We observed an inhibition of activation-induced proliferation of both T and B wild-type cells by Fas:Fc, whereas FasL triggering by Fas:Fc had no influence on the proliferation of reverse signaling-incompetent *FasL ΔIntra* cells (supplemental Figure 10). This is in agreement with our previous result and with data presented by Paulsen et al,<sup>11</sup> according to which FasL reverse signaling inhibits activation-induced proliferation of lymphocytes.

Several publications present evidence that the nascent FasL molecule is targeted, via its PRD, to specialized secretory lysosomes present in lymphocytes.<sup>44,45</sup> The lysosomes then undergo fusion with the plasma membrane at the site of contact with the target cell to deliver their cytotoxic cargo. However, analysis of our knockout/knockin mouse model, which completely lacks the FasL ICD, did not provide in vivo evidence for an important role of FasL PRD-dependent sorting of the molecule. Constitutive expression of truncated FasL at the cell surface of T, B, and natural killer cells due to the lack of the PRD domain would probably result in massive induction of apoptosis. Such increased cell killing (leading to pathological consequences) appears likely because, in contrast to human FasL, membrane-bound FasL is the primary functional form of murine FasL.<sup>46</sup> It is because of this that we would not expect increased shedding of surface FasL to compensate for the constitutive delivery and expression of FasL at the cell surface. In addition, our experiments with ex vivo isolated cells did not reveal significant differences in the FasL-dependent killing of target cells by CTLs, and the in vivo FasL expression and killing level in different cell types is large enough to prevent development of the *gld* phenotype. In agreement with our findings, 2 independent lines of evidence suggest the possibility that FasL is sorted to the cell surface of hematopoietic effector cells by alternative pathways independent of the FasL ICD. First, recent studies did not confirm colocalization of FasL with classical markers or components of secretory lysosomes, suggesting storage in other compartments.<sup>47-49</sup> An alternative pathway for FasL sorting to the cell surface has been suggested, possibly involving the FasL binding proteins Grb2<sup>50</sup> and Adaptin 2.<sup>51</sup> Furthermore, removal of the PRD has been correlated with increased FasL cell surface expression on rat basophil leukemia cells. However 70% of these mutant FasL molecules remain intracellular,<sup>44</sup> arguing against constitutive delivery of FasL in the absence of the cytoplasmic domain.

In summary, our *FasL ΔIntra* mouse model data confirms an inhibitory function for FasL reverse signaling in lymphocyte

activation, which may prevent hyperactivation of lymphocytes in response to antigen stimulation. It is worth speculating whether this immune modulation by FasL signal transduction is important for the termination of immune responses and for the prevention of overwhelming inflammation in autoimmunity or allergy, a theory that will be tested in adequate mouse models in the future.

## Acknowledgments

We thank Susanne Bösser, Gabriele Marschall-Schröter, Sandra Geissler, Kerstin Kutzner, and Christine Fürmann for excellent technical assistance.

This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG; ZO110/4-1; ZO110/2-1/2, to M.Z.), the German National Academic Foundation (to K.L.), the European Union (EUMODIC LSHG-2006-037188, German Mouse Clinic), and the German National Genome Research Network (NGFN project N1KR-S12T23, to M.Z.; NGFNplus 01GS0850 to M.H.d.A., 01GS0852 to D.B., 01GS0868 to M.O.).

## Authorship

Contribution: V.K. and G.M. established the mouse model; K.L., I.M.M., K.R., F.T., D.S., L.J.S., and U.Z.-S. performed experiments and analyzed the data; W.M. performed the FasL ICD Y2H screen; A.A.P., T.A., D.B., M.O., M.H., and J.B. conducted a systematic phenotypic analysis of the *FasL ΔIntra* mouse model; M.H.d.A., V.G.-D., H.F., F.J.T.S., A.-O.H., and U.Z.-S. contributed to the design of the experiments and the analysis of data; and K.L. and M.Z. conceived the study and wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

The current affiliation for Vladimir Kirkin is Merck-Serono/Research and Development/Oncology, In Vivo Pharmacology, Merck KGaA, Darmstadt, Germany. The current affiliation for Wiebke Milani is Institut für Physiologie und Pathophysiologie, University of Marburg, Marburg, Germany. The current affiliation for Geert Michel is Charité- Universitätsmedizin Berlin, Campus Benjamin Franklin, Transgene Technologien, Berlin, Germany.

Correspondence: Martin Zörnig, Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, Paul-Ehrlich-Strasse 42-44, D-60596 Frankfurt, Germany; e-mail: zoernig@em.uni-frankfurt.de.

## References

- Voss M, Lettau M, Paulsen M, Janssen O. Post-translational regulation of Fas ligand function. *Cell Commun Signal*. 2008;6:11.
- Fas SC, Fritzsching B, Suri-Payer E, Krammer PH. Death receptor signaling and its function in the immune system. *Curr Dir Autoimmun*. 2006;9:1-17.
- Ferguson TA, Griffith TS. A vision of cell death: Fas ligand and immune privilege 10 years later. *Immunol Rev*. 2006;213:228-238.
- Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. *Immunol Today*. 1995;16(1):39-43.
- Kavurma MM, Khachigian LM. Signaling and transcriptional control of Fas ligand gene expression. *Cell Death Differ*. 2003;10(1):36-44.
- Peter ME, Budd RC, Desbarats J, et al. The CD95 receptor: apoptosis revisited. *Cell*. 2007;129(3):447-450.
- Sancho-Martinez I, Martin-Villalba A. Tyrosine phosphorylation and CD95: a FAScinating switch. *Cell Cycle*. 2009;8(6):838-842.
- Suzuki I, Fink PJ. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. *J Exp Med*. 1998;187(1):123-128.
- Desbarats J, Duke RC, Newell MK. Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells. *Nat Med*. 1998;4(12):1377-1382.
- Sun M, Lee S, Karray S, Levi-Strauss M, Ames KT, Fink PJ. Cutting edge: two distinct motifs within the Fas ligand tail regulate Fas ligand-mediated costimulation. *J Immunol*. 2007;179(9):5639-5643.
- Paulsen M, Mathew B, Qian J, Lettau M, Kabelitz D, Janssen O. FasL cross-linking inhibits activation of human peripheral T cells. *Int Immunol*. 2009;21(5):587-598.
- Kirkin V, Cahzac N, Guardiola-Serrano F, et al. The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells. *Cell Death Differ*. 2007;14(9):1678-1687.
- Baum W, Kirkin V, Fernandez SB, et al. Binding of the intracellular Fas ligand (FasL) domain to the adaptor protein PSTPIP results in a cytoplasmic localization of FasL. *J Biol Chem*. 2005;280(48):40012-40024.
- Cahzac N, Baum W, Kirkin V, et al. Fas ligand is localized to membrane rafts, where it displays increased cell death-inducing activity. *Blood*. 2006;107(6):2384-2391.
- Fuchs H, Gailus-Durner V, Adler T, et al. The German Mouse Clinic: a platform for systemic phenotype analysis of mouse models. *Curr Pharm Biotechnol*. 2009;10(2):236-243.
- Gailus-Durner V, Fuchs H, Adler T, et al. Systemic first-line phenotyping. *Methods Mol Biol*. 2009;530:463-509.
- Rastelli J, Homig-Holzel C, Seagal J, et al. LMP1 signaling can replace CD40 signaling in B cells in

- vivo and has unique features of inducing class-switch recombination to IgG1. *Blood*. 2008; 111(3):1448-1455.
18. Swanson CL, Wilson TJ, Strauch P, Colonna M, Pelanda R, Torres RM. Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response. *J Exp Med*. 2010;207(7):1485-1500.
  19. Toellner KM, Luther SA, Sze DM, et al. T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. *J Exp Med*. 1998;187(8):1193-1204.
  20. Krishna M, Narang H. The complexity of mitogen-activated protein kinases (MAPKs) made simple. *Cell Mol Life Sci*. 2008;65(22):3525-3544.
  21. Hikida M, Kurosaki T. Regulation of phospholipase C-gamma2 networks in B lymphocytes. *Adv Immunol*. 2005;88:73-96.
  22. Staal FJ, Luis TC, Tiemessen MM. WNT signaling in the immune system: WNT is spreading its wings. *Nature Rev Immunol*. 2008;8(8):581-593.
  23. Jin ZX, Kishi H, Wei XC, Matsuda T, Saito S, Muraguchi A. Lymphoid enhancer-binding factor-1 binds and activates the recombination-activating gene-2 promoter together with c-Myb and Pax-5 in immature B cells. *J Immunol*. 2002;169(7):3783-3792.
  24. Reya T, O'Riordan M, Okamura R, et al. Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. *Immunity*. 2000;13(1):15-24.
  25. Peng SL, Gerth AJ, Ranger AM, Glimcher LH. NFATc1 and NFATc2 together control both T and B cell activation and differentiation. *Immunity*. 2001;14(1):13-20.
  26. Ahn KS, Sethi G, Aggarwal BB. Nuclear factor-kappa B: from clone to clinic. *Curr Mol Med*. 2007;7(7):619-637.
  27. Mittrucker HW, Matsuyama T, Grossman A, et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. *Science*. 1997;275(5299):540-543.
  28. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. *Nature*. 1999;398(6726):422-426.
  29. Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC. Survivin and molecular pathogenesis of colorectal cancer. *Lancet*. 2003;362(9379):205-209.
  30. Durmowicz MC, Cui CY, Schlessinger D. The EDA gene is a target of, but does not regulate Wnt signaling. *Gene*. 2002;285(1-2):203-211.
  31. Kratochwil K, Galceran J, Tontsch S, Roth W, Grosschedl R. FGF4, a direct target of LEF1 and Wnt signaling, can rescue the arrest of tooth organogenesis in Lef1(-/-) mice. *Genes Dev*. 2002;16(24):3173-3185.
  32. Hebenstreit D, Giaisi M, Treiber MK, et al. LEF-1 negatively controls interleukin-4 expression through a proximal promoter regulatory element. *J Biol Chem*. 2008;283(33):22490-22497.
  33. Sun M, Fink PJ. A new class of reverse signaling costimulators belongs to the TNF family. *J Immunol*. 2007;179(7):4307-4312.
  34. Wilczynski JR, Radwan M, Kalinka J. The characterization and role of regulatory T cells in immune reactions. *Front Biosci*. 2008;13:2266-2274.
  35. Oehme I, Neumann F, Bosser S, Zornig M. Transgenic overexpression of the Caspase-8 inhibitor FLIP(short) leads to impaired T cell proliferation and an increased memory T cell pool after staphylococcal enterotoxin B injection. *Eur J Immunol*. 2005;35(4):1240-1249.
  36. Hahne M, Renno T, Schroeter M, et al. Activated B cells express functional Fas ligand. *Eur J Immunol*. 1996;26(3):721-724.
  37. Lundy SK, Lerman SP, Boros DL. Soluble egg antigen-stimulated T helper lymphocyte apoptosis and evidence for cell death mediated by FasL(+) T and B cells during murine *Schistosoma mansoni* infection. *Infect Immun*. 2001;69(1):271-280.
  38. Nagafuchi H, Wakisaka S, Takeba Y, Takeno M, Sakane T, Suzuki N. Aberrant expression of Fas ligand on anti-DNA autoantibody secreting B lymphocytes in patients with systemic lupus erythematosus: "immune privilege"-like state of the auto-reactive B cells. *Clin Exp Rheumatol*. 2002;20(5):625-631.
  39. Lundy SK. Killer B lymphocytes: the evidence and the potential [published online ahead of print March 5, 2009]. *Inflamm Res*. doi: 10.1007/s00011-009-0014-x.
  40. Arce L, Yokoyama NN, Waterman ML. Diversity of LEF/TCF action in development and disease. *Oncogene*. 2006;25(57):7492-7504.
  41. Arimura Y, Vang T, Tautz L, Williams S, Mustelin T. TCR-induced downregulation of protein tyrosine phosphatase PEST augments secondary T cell responses. *Mol Immunol*. 2008;45(11):3074-3084.
  42. Davidson D, Veillette A. PTP-PEST, a scaffold protein tyrosine phosphatase, negatively regulates lymphocyte activation by targeting a unique set of substrates. *EMBO J*. 2001;20(13):3414-3426.
  43. Yang H, Reinherz EL. CD2BP1 modulates CD2-dependent T cell activation via linkage to protein tyrosine phosphatase (PTP)-PEST. *J Immunol*. 2006;176(10):5898-5907.
  44. Blott EJ, Bossi G, Clark R, Zvebil M, Griffiths GM. Fas ligand is targeted to secretory lysosomes via a proline-rich domain in its cytoplasmic tail. *J Cell Sci*. 2001;114(Pt 13):2405-2416.
  45. Zuccato E, Blott EJ, Holt O, et al. Sorting of Fas ligand to secretory lysosomes is regulated by mono-ubiquitylation and phosphorylation. *J Cell Sci*. 2001;114(Pt 13):191-199.
  46. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human fas ligand in activated lymphocytes. *EMBO J*. 1995;14(6):1129-1135.
  47. He JS, Ostergaard HL. CTLs contain and use intracellular stores of FasL distinct from cytolytic granules. *J Immunol*. 2007;179(4):2339-2348.
  48. Kassahn D, Nachbur U, Conus S, et al. Distinct requirements for activation-induced cell surface expression of preformed Fas/CD95 ligand and cytolytic granule markers in T cells. *Cell Death Differ*. 2009;16(1):115-124.
  49. Xiao S, Deshmukh US, Jodo S, et al. Novel negative regulator of expression in Fas ligand (CD178) cytoplasmic tail: evidence for translational regulation and against Fas ligand retention in secretory lysosomes. *J Immunol*. 2004;173(8):5095-5102.
  50. Thornhill PB, Cohn JB, Stanford WL, Desbarats J. The adaptor protein Grb2 regulates cell surface Fas ligand in Schwann cells. *Biochem Biophys Res Commun*. 2008;376(2):341-346.
  51. Thornhill PB, Cohn JB, Drury G, Stanford WL, Bernstein A, Desbarats J. A proteomic screen reveals novel Fas ligand interacting proteins within nervous system Schwann cells. *FEBS Lett*. 2007;581(23):4455-4462.